SGD-1882
| Code | Size | Price |
|---|
| TAR-T19560-1mg | 1mg | £1,990.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
SGD-1882 is a agent of cytotoxic, DNA minor-groove crosslinking pyrrolobenzodiazepine (PBD) dimer, and acting as the payload for ADCs.
CAS:
1222490-34-7
Formula:
C42H39N5O7
Molecular Weight:
725.802
Purity:
0.98
SMILES:
[H][C@@]12CC(=CN1C(=O)c1cc(OC)c(OCCCOc3cc4N=C[C@]5([H])CC(=CN5C(=O)c4cc3OC)c3ccc(OC)cc3)cc1N=C2)c1ccc(N)cc1
References
1. Eunhee G. Kim, et al. Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics. Biomol Ther (Seoul). 2015 Nov; 23(6): 493-509.
2. Dowdy Jackson, et al. Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates. Pharm Res. 2015; 32(11): 3458-3469.